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Objective: Skeletal myoblast transplantation is a promising alternative to treat heart
failure. A single fiber, the minimal functional unit of skeletal muscle, retains skeletal
myoblasts beneath the basal lamina. When surrounding muscle is injured, myoblasts
migrate from the fiber into the damaged area to regenerate muscle. We hypothesized
that such isolated fibers could be used as an efficient vehicle to deliver myoblasts
into damaged myocardium, resulting in improved cardiac function.
Methods: Living single fibers of rat skeletal muscle were isolated, and their behavior
was characterized in vitro. Single fibers were injected into the myocardium (at 4
sites, each receiving a single fiber) of rats in 2 models of heart failure induced either
by means of doxorubicin administration or left coronary artery occlusion.
Results: Skeletal myoblasts dissociated from an isolated single fiber, proliferated,
and differentiated into multinucleated myotubes in vitro. Within 3 days after grafting in
vivo, original fibers provided putative myoblasts and disappeared. At 4 weeks, discrete
loci consisting of several multinucleated myotubes were observed. Furthermore, single-
fiber transplantation significantly improved cardiac function compared with the control
treatment in either doxorubicin-treated hearts (maximum dP/dt, 4013.9  96.1 vs
3603.1  102.3 mm Hg/s; minimum dP/dt, 2313.7  75.1 vs 2057.1  52.4 mm
Hg/s) or ischemic hearts (maximum dP/dt, 3905.6  103.0 vs 3572.6  109.7 mm
Hg/s; minimum dP/dt, 2336.1  69.7 vs 2106.4  74.2 mm Hg/s).
Conclusion: Single-fiber transplantation acts as a vehicle for delivering putative
skeletal myoblasts that appear to differentiate into myotubes within the myocar-
dium. This was associated with improved function of failing hearts, suggesting its
efficacy as a novel graft for cellular cardiomyoplasty.
Skeletal myoblast transplantation is a promising alternative strategy totreat end-stage heart failure.1-4 It has been demonstrated that skeletalmyoblasts retain the ability to regenerate differentiated functionalmuscle and to improve cardiac function when transplanted in rabbitand rat heart failure models.3,4 In addition, myoblasts can be isolatedfrom patients with heart failure themselves and used as an autograft,
obviating the need for immunosuppressive reagents.5 Currently, direct intramyocar-
dial injection of a skeletal myoblast suspension is the most popular method to
deliver myoblasts into the heart. However, we consider that there remain some
important issues that should be addressed to refine this therapeutic strategy for
clinical application. One of these is the time-consuming and complex process
required to prepare sufficient numbers of purified myoblasts from skeletal muscle.
Millions of myoblasts are likely to be required to improve cardiac function by means
of direct intramyocardial injection of a skeletal myoblast suspension, even in small
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animals.3,4 There are concerns that repeated passaging of
primary myoblasts in vitro might cause possible harmful
effects, resulting in the alteration of important properties,
such as the ability to fuse and differentiate.6
Recently, we have established a simple, quick technique
to isolate viable single fibers of rodent skeletal muscle.6 A
single fiber (here defined as muscle tissue separated into
individual fibers), the minimal functional unit of skeletal
muscle, retains myogenic precursors, skeletal myoblasts
(satellite cells), between the basal lamina and plasma mem-
brane. The myoblasts are normally mitotically quiescent,
but when surrounding muscle is injured, they migrate from
the fiber into the damaged area, proliferating and differen-
tiating to regenerate myofibers.7,8 In this study we investi-
gated whether transplanted single fibers could work as a
vehicle to deliver skeletal myoblasts-myotubes into the
myocardium and whether this strategy leads to the improve-
ment of cardiac function in heart failure induced by either
doxorubicin administration or myocardial infarction.
Methods
Animal Care
All studies were performed with the approval of the institutional
ethics committee for animal research and the Home Office. The
investigation conforms to the “Principles of Laboratory Animal
Care” formulated by the National Society for Medical Research
and the “Guide for the Care and Use of Laboratory Animals”
published by the US National Institutes of Health (publication No.
85-23, 1996).
Isolation of Single Muscle Fibers
Living single fibers of skeletal muscle were isolated according to
the previously described method.6,7 Briefly, the extensor digitorum
longus of a male Lewis rat (80 g) was removed and digested in
0.2% type I collagenase (Sigma) in Dulbecco’s modified Eagle’s
medium (DMEM). The muscle was transferred to a petri dish
containing serum-free DMEM, in which single muscle fibers were
liberated by means of gentle trituration. The individual, intact,
viable muscle fibers (approximately 500 m long and 20 m in
diameter) were collected and subsequently injected into the heart,
as described below.
Characterization of Single Muscle Fibers and Derived
Myoblasts
When cultured in proliferation medium (DMEM with 20% fetal
calf serum, 10% horse serum, and 0.5% chicken embryo extract),
putative skeletal myoblasts were derived from the fibers and pro-
liferated. Cells were grown to subconfluence in proliferation me-
dium, which was then switched to differentiation medium (DMEM
with 2% horse serum) to induce differentiation.6 Cells were incu-
bated to subconfluence to assess the purity of myoblast culture.
After fixation and blocking, the samples were incubated in anti-
-sarcomeric actin monoclonal antibody (Dako) and then in fluo-
rescein isothiocyanate–conjugated secondary antibody (Dako).
Nuclei were counterstained with 4,6-diamino-2-phenylindole.
Generation of Doxorubicin- or Myocardial Infarction–
induced Heart Failure
Heart failure was induced by means of doxorubicin administra-
tion9,10 or left coronary artery (LCA) occlusion11 in male Lewis
rats (200 g). Fifty rats were administered with doxorubicin hydro-
chloride (Sigma) in 6 equal injections (each containing 2.5 mg/kg
in saline solution administered intraperitoneally) over a period of
2 weeks for a total dose of 15 mg/kg. Another 45 rats were
anesthetized with sodium pentobarbital (50 mg/kg administered
intraperitoneally) and mechanically ventilated. Through a left tho-
racotomy, the LCA was occluded 3 mm distal to its origin. The
surgical wounds were repaired, and the rats were returned to their
cages to recover. Aseptic surgical techniques were used throughout
the procedure. Rats were observed for 4 weeks after the last
injection of doxorubicin or LCA occlusion for their general ap-
pearance, behavior, and mortality.
Transplantation of Syngeneic Single Fibers into the
Failing Rat Heart
Four weeks after the last doxorubicin injection or LCA occlusion,
appropriately randomized rats were anesthetized and mechanically
ventilated. Through a left thoracotomy, single fibers of a syngeneic
donor (although not autografts) were injected into the left ventric-
ular (LV) free wall (at 4 sites, each of which was injected with only
one fiber in 3 L of DMEM) with a glass micropipette (Drum-
mond Scientific), the end of which was pulled to an extremely
sharp point after heating (n  20 for the doxorubicin model). For
the LCA-occluded hearts (n  18), fibers were injected into the
border zone of infarcts (not into infarct scar). We believe that
injection into the border zone has some potential advantages over
the injection into the infarct scar, including easier injection and
better blood supply for grafted cells. For the control group, the
same volume of DMEM was injected (n  20 for each model).
After repairing surgical wounds, the rats were incubated for a
further 4 weeks.
Histologic Study
At 4 weeks after transplantation, hearts from each group were
collected, and the left ventricle was cut into 4 segments and frozen
in an embedding medium. After fixation, 6-m cryosections were
incubated with 0.6% H2O2 in 0.1% Triton X-100. After blocking,
the sections were incubated with an anti-skeletal myosin heavy
chain (MHC) antibody (Zymed laboratories), which reacts with
skeletal MHC but not with cardiac or smooth muscle myosin. This
was then incubated with a biotinylated secondary antibody (Dako).
The sections were colored with a Dako streptABComplex/HRP kit,
according to the manufacturer’s instructions, and counterstained
with hematoxylin and eosin. Sections were examined by blinded
experienced histologists. The number of capillary vessels in the
peri-infarct area was counted with a light microscope at 400
magnification by blinded experienced observers on the sections
that included injection sites.12 Five such high-power fields (HPFs)
in each section were randomly selected, and the number of capil-
laries in each field was averaged and expressed as the number of
capillary vessels per HPF (0.2 mm2).
Assessment of Cardiac Function and Infarct Size
At 4 weeks after single-fiber transplantation, rats (n  8 in each
group) were anesthetized again as above. After systemic hepa-
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rinization, the hearts were quickly excised and perfused at 1 mH2O
pressure with modified Krebs-Henseleit buffer by using a Lange-
ndorff apparatus, as described previously.13 After 20 minutes of
stabilization, heart rate, ventricular function, balloon volume, and
coronary flow were measured with left ventricular end-diastolic
pressure (LVEDP) stabilized at 10 mm Hg by using a thin-walled
balloon. After perfusion, the hearts undergoing LCA occlusion
were fixed in 3.7% neutral-buffered formaldehyde, and the left
ventricle was cut into 5 segments parallel to the apex-base axis. A
10-m section from each segment was stained with Masson
trichrome and projected onto a screen for computer-assisted
planimetry. The ratio of scar length to LV circumferences of the
endocardium and epicardium was determined by blinded experi-
enced histologists and expressed as a percentage to define infarct
size.11
Study for Dynamics of Original Single Fibers
-Galactosidase (-gal)–expressing single fibers of EDL muscle,
obtained from a 3F-nlacZ-2E transgenic mouse,14 were implanted
into the hearts of male athymic (nude) rats (150-200 g, Charles
River UK Ltd)15 to further investigate the dynamics of grafted
original fibers after implantation into the heart. The 3F-nlacZ-2E
mouse, kindly provided by Dr M. Buckingham (Department of
Molecular Biology, Institute Pasteur, France), carried regulatory
elements from the locus of the fast myosin light-chain 2F/3F gene
that drives a nlacZ reporter gene, and this transgene is expressed
by all myonuclei in fast myofibers.14 Such -gal–expressing single
fibers and migrated myoblasts could be more clearly identified in
the host myocardium by means of in situ staining for -gal. Nude
rats were used as recipients to remove the need for immunosup-
pression. Isolation of single fibers and transplantation into the heart
were performed exactly as described above. Heart samples were
collected at 1 hour, 1 day, and 3 days after grafting (n  3 at each
time point); cut into 4 segments; and frozen in an embedding
medium. The samples were cut into 10-m cryosections, fixed in
2% formaldehyde and 0.2% glutaraldehyde, and then stained with
1 mg/mL 5-bromo-4-chloro-3-indoyl--D-galactopyranoside, 5
mmol/L potassium ferricyanide, 5 mmol/L potassium ferrocya-
nide, and 2 mmol/L MgCl2 for 12 to 16 hours at 37°C.13 The
sections were counterstained with hematoxylin.
Statistical Analysis
All values are expressed as means  SEM. Statistical comparison
of the data was performed by using a Student t test with the
Statview version 4.0 statistical package (Abacus Concepts Inc).
Results
Characteristics of Skeletal Muscle Fibers and Derived
Myoblasts
Putative skeletal myoblasts had dissociated from isolated,
living single-fiber explants of Lewis rats within 24 hours
after plating (Figure 1, A and B). Immunocytochemistry
demonstrated that all the cells were stained positively for
-sarcomeric actin (Figure 1, C), confirming the high purity
of the myoblast culture. The cells were cultured in prolif-
eration medium until subconfluence and then switched to
differentiation medium to examine their myogenic differen-
tiation ability. Consequently, the cells fused and differenti-
ated into multinucleated myotubes within a week (Figure 1,
D).
Histologic Findings after Single-fiber Transplantation
Discrete loci, positively stained for skeletal MHC, were
observed in every doxorubicin-treated heart at 4 weeks after
single-fiber transplantation at 27 of the total of 40 injection
sites studied under low-power magnification (Figure 2, B).
Because this antibody reacts with skeletal MHC but not
with cardiac or smooth muscle myosin, these positively
stained cells were presumed to be of skeletal myoblast
origin. Each of these loci consisted of several discrete,
branching, multinucleated myotubes that had aligned with
the cardiac fiber axis within native myocardium at the
injection site where only one myotube (single fiber) had
been implanted (Figure 2, C and D). Such loci, consisting of
several multinucleated myotubes positively stained for skel-
etal MHC, were also observed locally in the peri-infarct area
of every LCA-occluded heart at 4 weeks after single-fiber
transplantation at 20 of the 32 injection sites (Figure 3, B).
These differentiated, branching, multinucleated myotubes
had aligned with the cardiac fiber axis within native myo-
cardium, which is similar to that observed in the doxorubi-
cin-treated hearts (Figure 3, C). Furthermore, angiogenesis
induction with mature capillaries was observed in the sur-
rounding area of the grafted myotubes in the single fiber–
transplanted hearts (Figure 3, D). Local capillary density
was significantly (P  .0046) higher in the single fiber–
transplanted hearts compared with that in the control-treated
hearts (4.1  0.5 vs 2.3  0.2 vessels/HPF, n  8 for the
single fiber–transplanted hearts and n  6 for the control-
treated hearts).
Dynamics of Original Single Fibers Grafted Into
Myocardium
-Gal–expressing single fibers were implanted into the
hearts to further clarify the dynamics of grafted original
fibers. In situ staining for -gal demonstrated that -gal–
positive surviving single fibers existed in the myocardium 1
hour after implantation (Figure 4, A) but not in day 1 (Figure
4, B) or 3 (Figure 4, C) samples. At day 1 after grafting, a
mass of -gal–positive debris, presumably originated from
a destroyed single fiber, was observed (Figure 4, B). At day
3, such -gal–positive debris also disappeared, and instead,
-gal–positive cells (putative skeletal myoblasts migrated
from grafted fiber) were found (Figure 4, C).
Cardiac Function After Single-fiber Transplantation
The effect of single-fiber transplantation on cardiac function
was investigated by using 2 different heart failure models,
caused by either doxorubicin administration or LCA liga-
tion. Before the main part of the study, we confirmed
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consistency of functional reduction in these models by using
Langendorff isolated heart perfusion. In comparison with
the baseline data of normal intact hearts (left ventricular
developed pressure [LVDP], 151.6  2.3 mm Hg; maxi-
mum dP/dt, 4554.3  50.1 mm Hg/s; minimum dP/dt,
3298.4 35.4 mm Hg/s at 10 mm Hg of LVEDP, n 8),
cardiac function was significantly reduced at 1 month after
doxorubicin administration (LVDP, 124.8  3.4 mm Hg;
maximum dP/dt, 3631.2  78.8 mm Hg/s; minimum dP/dt,
2239.6 46.0 mm Hg/s; n 5, P .001) and LCA ligation
(LVDP, 126.9 3.6 mm Hg; maximum dP/dt, 3687.4 84.1
mm Hg/s; minimum dP/dt, 2263.7.2  56.2 mm Hg/s; n 
7, P  .001). Then Langendorff perfusion was performed to
assess the functional benefits of single-fiber transplantation 4
weeks after the treatment (Table 1). As regards doxorubicin-
induced heart failure, LVDP and maximum and minimum
dP/dt at 10 mm Hg of LVEDP were significantly improved in
the single fiber–transplanted hearts compared with that seen in
the medium-injected hearts. LV chamber size at 10 mm Hg of
LVEDP was significantly smaller in the single fiber–trans-
planted hearts. Similarly, in LCA occlusion–induced heart
failure, all of these parameters for both systolic and diastolic
function were improved in the single fiber–transplanted hearts
associated with higher coronary flow. In addition, these data
concerning improved function by means of single-fiber trans-
plantation in LCA-occluded hearts were associated with de-
creased infarct size in comparison with the that in the control
hearts (36.5%  1.5% vs 43.3%  1.8%, n  8, P  .0109).
Heart rate was not different between the single fiber–trans-
planted and medium-injected hearts in either heart failure
model.
Mortality
Mortality during the 4-week period after the final doxoru-
bicin injection or LCA occlusion until single-fiber trans-
plantation was 28.0% (14/50) and 24.4% (11/45), respec-
tively. Mortality at 4 weeks after single-fiber transplantation
was 10.0% (2/20) in the doxorubicin-induced heart failure
Figure 1. Single muscle fibers and derived myoblasts. A and B, Single fibers were isolated from rat skeletal muscle,
from which skeletal myoblasts dissociated within 24 hours after plating (reverse-phase contrast microscopic
observation). C, All the derived cells were stained green (fluorescein isothiocyanate) for -sarcomeric actin.
Nuclei were counterstained blue with 4,6-diamino-2-phenylindole. D, The dissociated cells fused and differenti-
ated into multinucleated myotubes after switching into differentiation medium. The scale bar indicates 250 m in
A and 50 m in B, C, and D.
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model and 11.1% (2/18) in the LCA occlusion model com-
pared with 12.5% (2/16) in the doxorubicin-induced heart
failure model and 12.5% (2/16) in the LCA occlusion model
after medium injection.
Discussion
We have demonstrated that single fibers of skeletal muscle
grafted to the heart provide putative skeletal myoblasts that
appear to differentiate into multinucleate myotubes within
the myocardium. This in vivo behavior of grafted single
fibers is equivalent to the in vitro observation that has been
shown in the present and in other articles.6,7 Our study using
implantation of -gal–expressing single fibers demon-
strated that all the grafted original fibers are destroyed and
subsequently removed after providing myoblasts into myo-
cardium within 3 days after grafting. We have also de-
scribed that, 4 weeks after syngeneic single-fiber transplan-
tation, several discrete multinucleated myotubes are formed
at each injection site where only one myotube (single fiber)
had been implanted. These multinucleated myotubes were
branching and appeared to be aligned with the cardiac fiber
axis, showing a different appearance from the original sin-
gle fiber. Because the mature myonuclei of the original fiber
are postmitotic, these data indicates that skeletal myoblasts,
which are derived from the parent fiber, are the source of the
newly formed multinucleated myotubes.
Furthermore, we have shown that such single-fiber trans-
plantation results in improvement of cardiac function in 2
different types of heart failure induced by either doxorubi-
cin treatment or LCA occlusion, suggesting the feasibility
of this strategy for treating heart failure. Both heart failure
models used here have been established as stable and reli-
able models clinically relevant to idiopathic and ischemic
cardiomyopathy, respectively.9-11 Such consistent signifi-
cant reduction in cardiac function at 1 month after doxoru-
bicin administration and LCA ligation in comparison with
our baseline data of normal intact hearts was confirmed in
our own study. A limitation of using the Langendorff per-
fusion system with isolated hearts is the inability to measure
the time course of functional changes in a single animal
throughout the pretreatment and posttreatment period. Thus
this system would not be optimal to study the degree of
functional improvement after single-fiber transplantation
Figure 2. Histologic findings in doxorubicin-induced heart failure. As a result of immunostaining for skeletal MHC
(counterstained with hematoxylin and eosin), groups of positively stained, differentiated, multinucleated myotubes
(yellow arrows) were observed in the doxorubicin-treated hearts at 4 weeks after single-fiber transplantation
(B-D), whereas no cells were stained in medium-injected hearts (A). The scale bar indicates 100 m in A, B, and
C and 25 m in D.
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compared with that before transplantation. In this study we
therefore focused on the comparison of function between
single fiber–treated hearts and sham-treated hearts at the
same time point using randomized, diseased rats that had
consistent myocardial damage caused by either doxorubicin
administration or LCA ligation. As a result, we found a
decrease in diastolic compliance in the control-treated
hearts compared with that in the single fiber–treated rats in
both heart failure models. This might have affected the data
of systolic function to some extent; however, it is unlikely
that such remarkable improvement both in terms of LVDP
and maximum dP/dt, as demonstrated in our data, resulted
from such a difference in diastolic function. Further study is
needed to evaluate more detailed functional analysis after
single-fiber engraftment, including ventricular chamber size
and time course.
The use of single fibers could be advantageous over the
conventional method of direct intramyocardial injection of a
myoblast suspension in several respects. Foremost, the sin-
gle-fiber protocol avoids the need for the prolonged in vitro
processes required to derive an adequate number of myo-
blasts for transplantation. During this several-week period,
repeated passaging is likely to be detrimental, and extended
incubation carries risks of infection of the primary culture
by means of bacteria, fungi, mycoplasma, and viruses. Fur-
thermore, this prolonged in vitro culture might thus cause
possible subtle changes in the myoblasts that render them
either more visible to the host immune system or less
competent for fusion and differentiation in vivo. In contrast,
preparations of single fibers can be completed within only a
few hours, avoiding the hazards of culture. This feature
could be of great significance, particularly in clinical set-
tings. Such easily harvested single fibers would also be
promising as grafts in relatively urgent situations. In human
patients the use of extensor digitorum longus might not be
suitable because single-fiber preparation requires muscle
from tendon to tendon. However, there are many other
potential sites for harvesting smaller skeletal muscle fibers
in human patients, including the digits, which would be
clinically applicable. Another advantage of using single
fibers is the lesser amount of medium required for injection.
A single fiber can be suspended in only 2 to 3 L of
Figure 3. Histologic findings in infarction-induced heart failure. Immunohistochemistry for skeletal MHC (coun-
terstained with hematoxylin and eosin) showed an infarction without skeletal MHC positively stained cells in the
LCA-occluded hearts treated by means of medium injection (A). Discrete loci composed of differentiated multinu-
cleated myotubes, which were stained brown for skeletal MHC (yellow arrows), were observed in the peri-infarct
area at 4 weeks after single-fiber transplantation (B and C). Angiogenesis with mature capillaries was observed
in the surrounding area (D). The scale bar indicates 100 m in A and B and 25 m in C and D.
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medium. One might expect a lesser injection volume of
medium to induce less host myocardial damage as a result
of inflammation after cell transplantation. A possible risk of
cell transplantation is an embolism caused by grafts leaked
into the systemic or coronary circulation. If grafted single
fibers leaked, it could easily cause embolism because of
their larger size. However, injection of single fibers is not
more difficult than injection of cultured cells and requires a
TABLE 1. Cardiac function in doxorubicin- or LCA occlusion–induced heart failure at day 28 after single-fiber transplan-
tation








Control 249.2 9.9 123.6 4.0 3603.1 102.3 2057.1 52.4 200.8 6.7 10.9 0.5
Single fiber 251.4 9.3 140.6 5.4 4013.9 96.1 2313.7 75.1 223.1 6.3 11.0 0.4
P value .9285 .0240 .0117 .0131 .0286 .9010
LCA occlusion
Control 265.2 10.8 122.3 4.3 3572.6 109.7 2106.4 74.2 174.6 6.3 10.1 0.4
Single fiber 261.9 11.2 137.5 5.0 3905.6 103.0 2336.1 69.7 201.4 8.6 11.8 0.4
P value .9044 .0363 .0365 .0376 .0257 .0084
Data were measured at 10 mm Hg of LVEDP. Values are expressed as means  SEM. n  8 in each group.
HR, Heart rate; CF, coronary flow; control, hearts infused with serum-free medium; single fiber, hearts grafted with single fibers.
Figure 4. Dynamics of grafted single fibers. -Gal– expressing single fibers obtained from a transgenic mouse were
implanted into the hearts to clarify the dynamics of grafted original fibers. As a result of in situ staining for -gal,
-gal–positive surviving single fibers were present in the myocardium at 1 hour after grafting (A) but broken into
debris at day 1 (B) and completely disappeared at day 3 (C). Instead, -gal–positive cells (putative skeletal
myoblasts migrated from grafted fiber) were observed at day 3 (C and D).
Evolving Technology Suzuki et al
990 The Journal of Thoracic and Cardiovascular Surgery ● May 2002
ET
smaller injection volume, resulting in a possibly lower risk
of leakage into the LV cavity or coronary vessels compared
with that seen in cell suspension grafting.
In the present study we have shown that as few as 4
single fibers grafted into the heart can improve global LV
function. Each single fiber from the Lewis rat extensor
digitorum longus retains approximately 20 skeletal myo-
blasts (satellite cells) according to the results of immuno-
staining for M-cadherin, a marker for skeletal myoblasts
(data not shown), suggesting that the myoblasts derived
from these fibers not only survive at a high rate but also
retain an adequate ability to proliferate and differentiate
within myocardium. A similarly high degree of survival and
differentiation is found when isolated mouse single fibers
are transplanted into skeletal muscle (data from Heslop and
associates, in preparation). Although further investigations
are needed to prove this concept in detail, we speculate that
using single muscle fibers as a vehicle for delivery of
myoblasts might afford natural protective mechanisms to
the myoblasts from environmental stress and subsequent
adverse pathologic processes, particularly in the early phase
after transplantation, which appears to be the most hazard-
ous period for grafted myoblasts.16,17 Original single fibers
grafted into the myocardium are so sensitive to such envi-
ronmental stress that they cannot survive for a long time
after grafting. Such injury could, at the same time, signal the
release of myoblasts, which we believe are the source of the
newly formed myotubes observed in our in vivo study.
The report by Scorsin and colleagues3 demonstrated that
transplantation of 5 million skeletal myoblasts improved LV
ejection fraction by 28.9% (measured by means of echocar-
diography) in rat ischemic hearts compared with that in
medium-injected rats. In the present study transplantation of
4 single fibers improved maximum dP/dt by 11.4% (mea-
sured with Langendorff perfusion) in a similar model. This
functional improvement seems to be less than half of the
previous report; however, these data cannot be compared
directly because several critical experimental conditions,
including the timing of grafting, are different. In addition,
one could expect that transplantation of more single fibers
would lead to greater improvement in cardiac function. The
extent of skeletal muscle engraftment and the number of
skeletal myotubes has not been measured in this study.
Although these measurements could be important in ex-
plaining enhanced myocardial function, we believe that the
quality of the engrafted cells, including proliferation and
differentiation capacity, contractile capacity, and gap junc-
tion formation ability, could be just as important in medi-
ating improvement. The capacity to secrete growth hor-
mones or cytokines is likely to contribute to improved
angiogenesis, as found in our study, or delayed myocardial
adverse remodeling, and thus this also might affect the
functional result. The fact that the myoblasts have not been
subjected to ex vivo culture and that the myoblasts localiz-
ing beneath the basal lamina of single fibers were protected
from the hazardous environmental stress at the time of
engraftment might explain the significant improvement in
function after transplantation of only 4 single fibers in the
rat heart. These issues need to be studied further.
We have also demonstrated that angiogenesis is induced
in infarcted hearts after single-fiber transplantation and that
this is associated with increased coronary flow. This finding
has been observed in previous reports with direct intramyo-
cardial injection of skeletal myoblasts.12 In addition, other
studies have shown that a nonspecific reaction caused by
mechanical injury results in angiogenesis induction in the
heart.18 In our study infarct size was reduced after single-
fiber transplantation in the hearts that had been subjected to
LCA occlusion 1 month before grafting compared with that
after medium injection. One month after LCA occlusion, the
myocardial scar is mature,11 and we would not expect
grafting at this point to significantly reduce infarct size,
although such angiogenesis might contribute to salvaging
ischemic hibernating host myocardium to some extent. Ap-
parent infarct size, as demonstrated by means of Masson
trichrome staining, might have been reduced because of
infiltration of the peri-infarct zone by surviving, newly
generated, skeletal myoblast–derived myotubes.
It has been reported that transplantation of sliced skeletal
muscle grafts into skeletal muscle itself results in extensive
migration of the donor myoblasts with improved graft cell
survival and fusion with host muscle.19 Although this is a
simple method for obtaining a source of myoblasts for
transplantation, as far as the heart is concerned, this type of
graft is unlikely to be suitable because of the greater phys-
ical constraints on graft size in the heart. This will even
reduce the function without perfect integration within the
heart. Minced skeletal muscle grafts might be an alternative
source of myoblasts for transplantation that avoids the pro-
longed period of in vitro culture. However, transplantation
of minced muscle has recently been shown to result in
failure to improve postinfarction cardiac function, possibly
as a result of an exaggerated inflammatory response caused
by implantation of multiple chunks of minced tissue.20 In
contrast, we have demonstrated that direct intramyocardial
injection of isolated, living single fibers results in formation
of newly generated and differentiated myotubes within the
host myocardium and improves cardiac function in both
doxorubicin- and myocardial infarction–induced heart fail-
ure models. These data suggest that single-fiber transplan-
tation could be potentially useful in treating heart failure.
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